Previous 10 | Next 10 |
2024-05-22 13:32:00 ET Summary Australia to ban compounded versions of Novo Nordisk's semaglutide and Eli Lilly's tirzepatide due to safety concerns. Existing home sales dipped 1.89% in April to 4.14 million. All eyes on Nvidia earnings but BofA points to another stock that de...
2024-05-22 11:25:25 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk office building fire brought under c...
2024-05-22 07:14:37 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Study finds 30% of Wegovy, Sax...
2024-05-21 16:45:23 ET RFK Jr. invests in GameStop, says will enact Wall Street reforms targeting short selling Parallel Universes? AI, Energy, And Chips BofA: Vertiv is the real AI stock darling since the boom SPYI ETF: Prepare For The Return Of Volatility ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 62.7% to $0.0589 on volume of 663,531,193 shares MGO Global Inc. (MGOL) rose 443.7% to $1.25 on volume of 324,879,411 shares Crown Electrokinetics Corp. (CRKN) fell 36.8% to $0.1257 on v...
2024-05-21 14:06:23 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk unsure when it will meet obesity dru...
2024-05-21 11:50:45 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Microcap Mangoceuticals doubles on plan to sell c...
2024-05-21 10:41:26 ET Eli Lilly's (NYSE: LLY) broad portfolio of drugs has helped the company's earnings climb over the years -- and in recent times, two products in particular have supercharged growth. The big pharma company sells Mounjaro and Zepbound, both prescribed for weight loss...
2024-05-21 10:29:09 ET More on Weight Loss Drugs Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead Genetics may determine who responds well to Wegovy: report One in eight U.S. adults admits to GLP-1 usage as public aware...
A look at the top 10 most actives in Canada iShares S&P/TSX 60 Index ETF (XIU) rose 0.2% to $34.19 on volume of 5,065,984 shares Lomiko Metals Inc. (LMR) rose 0.0% to $0.035 on volume of 3,159,378 shares Guanajuato Silver Company Ltd. (GSVR) rose 12.8% to $0.265 on volume of 2,856,082...
News, Short Squeeze, Breakout and More Instantly...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....
2024-07-24 06:39:00 ET If you're a dividend investor, you shouldn't bother with stocks that don't raise their payouts. Inflation has drastically chipped away at consumers' purchasing power in recent years, highlighting just how important it is for dividend income to rise over the long run...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...